Vizsgálati helyszín

Axon Clinical s.r.o.

Prague 5, 150 00, CsehországEU-13 felzárkózó országMég nincs intézményhez kötve

25futó vizsgálat
13lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 38 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Időskori makuladegeneráció16 vizsgálat
Diabéteszes retinopátia8 vizsgálat
Crohn-betegség5 vizsgálat
Migrén5 vizsgálat
Colitis ulcerosa4 vizsgálat
Parkinson-kór2 vizsgálat
Fázis: 3. fázis20 vizsgálat
2. fázis11 vizsgálat
2/3. fázis6 vizsgálat
4. fázis1 vizsgálat
Állapot: Fut, nem toboroz13 vizsgálat
Lezárult13 vizsgálat
Toboroz9 vizsgálat
Még nem toboroz3 vizsgálat
Fő szponzor: AbbVie5 vizsgálat
Janssen Research & Development, LLC4 vizsgálat
Takeda3 vizsgálat
Eyebiotech Limited2 vizsgálat
Ipsen2 vizsgálat
és még 22

Futó vizsgálatok

Még nem toboroz
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
2026-526648-11-00· 2/3. fázis· Shenzhen Oculgen Biomedical Technology Co. Ltd.· Forrás
Toboroz
A Study in Adults With Geographic Atrophy
NCT07606365· 2. fázis· Sitala Bio LTD· Forrás
Toboroz
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
2025-524894-17-00· 2/3. fázis· Eyebiotech Limited· Forrás
Toboroz
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776· 3. fázis· Amgen· Forrás
Fut, nem toboroz
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2025-523938-10-00· 3. fázis· Eyepoint Inc.· Forrás
Toboroz
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
2025-522231-34-00· 3. fázis· Alvotech Swiss AG· Forrás
Toboroz
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· 2. fázis· ONL Therapeutics· Forrás
Toboroz
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· 2. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· 2/3. fázis· EyeBiotech Ltd.· Forrás
Fut, nem toboroz
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· 3. fázis· EyePoint Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· 2/3. fázis· Eyebiotech Limited· Forrás
Fut, nem toboroz
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479· 2. fázis· AbbVie· Forrás
Toboroz
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· 3. fázis· Annexon, Inc.· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Fut, nem toboroz
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731· 3. fázis· Stealth BioTherapeutics Inc.· Forrás
Fut, nem toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950· 2. fázis· Takeda· Forrás
Toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593· 3. fázis· Belite Bio, Inc· Forrás
Fut, nem toboroz
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102· 3. fázis· AbbVie· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Fut, nem toboroz
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· 3. fázis· Cerevance· Forrás
Lezárult
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
NCT06591598· 4. fázis· Bayer· Forrás
Lezárult
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
2023-507207-66-00· 3. fázis· Oculis Operations S.a.r.l.· Forrás
Lezárult
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· 2. fázis· H. Lundbeck A/S· Forrás
Lezárult
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· 3. fázis· Ipsen· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457· 3. fázis· Ipsen· Forrás
Lezárult
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT05811351· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
NCT05536297· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Lezárult
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT05019521· 2. fázis· Alexion Pharmaceuticals Inc.· Forrás
Lezárult
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration
NCT04757636· 3. fázis· Opthea Limited· Forrás
Lezárult
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
NCT04770545· 3. fázis· Apellis Pharmaceuticals, Inc.· Forrás
Lezárult
Open-label Trial in Parkinson's Disease (PD)
NCT04760769· 3. fázis· AbbVie· Forrás

Helyszínadatok: EU CTIS (euclinicaltrials.eu)Frissítve: 2026. nov. 14.

Hibát jelzek